In case you hadn’t noticed, shares of BlackBerry Ltd. (NASDAQ: BBRY) have been on fire of late. The stock price is well above the old $9 buyout, and the stock was up a whopping 40% so far in 2014 to Thursday’s closing price of $10.45.
Now it appears as though some reality is setting in. The question is whether reality is merely a bump in the road.
CEO John Chen is making a huge difference. His efforts are taking the company away from raw production costs and designs. BlackBerry’s workforce is being sized appropriately. And now Chen even wants BlackBerry to do a sale-leaseback on its buildings and to sell unused or undeveloped space. A new Pentagon deal even got investors excited.
Citron Research recently came out and said that the negative metrics had changed. In fact, they even called for the stock to rise to $15 or more. Then a blog post from a writer who disclosed up front that he was long BlackBerry shares published this last Monday said that BlackBerry may be worth $17.
Top Integrated Utility Stocks To Own For 2015: MEDIFAST INC(MED)
Medifast, Inc., through its subsidiaries, engages in the production, distribution, and sale of weight management and disease management products, and other consumable health and diet products in the United States. The company?s product lines include weight and disease management, meal replacement, and vitamins. It also operates weight control centers that offer Medifast programs for weight loss and maintenance, customized patient counseling, and inbody composition analysis. The company markets its products under the Medifast and Essential brand names, including shakes, appetite suppression shakes, women?s health shakes, diabetics shakes, joint health shakes, coronary health shakes, calorie burn drinks, calorie burn flavor infusers, antioxidant shakes, antioxidant flavor infusers, bars, crunch bars, soups, chili, oatmeal, pudding, scrambled eggs, hot cocoa, cappuccino, chai latte, iced teas, fruit drinks, pretzels, puffs, brownie, pancakes, soy crisps, crackers, and omega 3 and digestive health products. Medifast Inc. sells its products through various channels of distribution comprising Web, call center, independent health advisors, medical professionals, weight loss clinics, and direct consumer marketing supported via the phone and the Web; Take Shape for Life, a physician led network of independent health coaches; and weight control centers. The company was founded in 1980 and is headquartered in Owings Mills, Maryland.
Advisors' Opinion:- [By Ben Levisohn]
Shares of Nutrisystem have gained 20% to $18.05 at 1:34 p.m., while Weight Watchers (WTW) has risen 3.6% to $39.42. Medifast (MED), however, has dropped 1.9% to $24.94.
Top Heal Care Companies To Watch For 2014: FibroGen Inc (FGEN)
FibroGen, Inc. (FibroGen) is a research-based biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics to treat unmet medical needs. The Company focuses in the areas of fibrosis and hypoxia-inducible factor (HIF) biology. FibroGen�� products include Roxadustat (FG-4592), which is an oral small molecule inhibitor of HIF prolyl hydroxylases (HIF-PHs), in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD), and FG-3019, which is a monoclonal antibody in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), pancreatic cancer and liver fibrosis. The Company�� subsidiaries include FibroGen Europe Oy (FibroGen Europe) and FibroGen China Anemia Holdings, Ltd. (FibroGen China).
Roxadustat is the HIF-PH inhibitor in Phase III clinical development, which acts by stimulating the body�� natural pathway of erythropoiesis, or red blood cell production. Roxadustat represents a new paradigm for the treatment of anemia in CKD patients and offers injectable erythropoiesis stimulating agents (ESAs). 1,449 subjects have participated in 26 completed Phase I and II clinical studies for roxadustat in North America, Europe and Asia. The Company, along with its collaboration partners, Astellas Pharma Inc., (Astellas) and AstraZeneca AB,(AstraZeneca), has designed a global Phase III program to support regulatory approval of roxadustat in both NDD-CKD and DD-CKD patients in multiple geographies.
FG-3019 is the Company�� fully-human monoclonal antibody that inhibits the activity of connective tissue growth factor (CTGF), a critical common element in the progression of fibrosis and associated diseases. In Phase II IPF clinical studies, FG-3019 demonstrated the stabilization of disease and, in human studies, reversal of lung fibrosis in some patients. In an open-label Phase II pancreatic cancer study of FG-3019 plus gemcitabine and erlotinib, FG-3019 demonstrated a dose-depen! dent improvement in one year survival rate. In 10 Phase I and Phase II clinical studies of FG-3019 to date involving over 340 subjects, FG-3019 has been tolerated across a range of doses studied, and there have been no dose-limiting toxicities observed as of November 13, 2014.
The Company competes with Threshold Pharmaceuticals, Inc., Gilead Sciences, Inc., Halozyme Therapeutics, Inc., Gilead Sciences, Inc., Celgene Corporation, Janssen Biotech, Inc., Johnson & Johnson, Inc., Sanofi, Novartis and Biogen Idec.
Advisors' Opinion:- [By John Udovich]
Recent IPO�FibroGen Inc (NASDAQ: FGEN) surged 22.96% today, reportedly after the journal Hepatology published the results of a workshop between the FDA and the American Association for the Study of Liver Disease (AASLD) which laid out criteria for a phase three study of a treatment for non-alcoholic steatohepatitis (NASH)���meaning its worth taking a closer look at the stock along with the performance of potential small cap or mid cap liver disease stock peers like Conatus Pharmaceuticals Inc (NASDAQ: CNAT), Intercept Pharmaceuticals Inc (NASDAQ: ICPT) and Raptor Pharmaceutical Corp (NASDAQ: RPTP) which rose 24.35%, 10.98% and 2.02%, respectively. According to Investors Business Daily, NASH (the more serious version of fatty liver disease) is potentially an enormous market with about 6 million�US patients but the�lack of previous treatments had left it unclear how the FDA would measure success against the disease while FibroGen Inc doesn't yet have a NASH human trial in the works, it has said it hopes to start one for its lead candidate FG-3019 (its in mid-stage trials for pulmonary fibrosis and liver fibrosis due to hepatitis B infection).
Top Heal Care Companies To Watch For 2014: Workday Inc (WDAY)
Workday, Inc., incorporated in March 2005, is a provider of enterprise cloud-based applications for human capital management (HCM), payroll, financial management, time tracking, procurement and employee expense management. It is focused on the consumer Internet experience and cloud delivery model. Its applications are designed for global enterprises to manage complex and dynamic operating environments. The Company provides its customers the applications to manage critical business functions for their financial and human capital resources. In February 2014, Workday Inc acquired Identified Inc, a provider of online recruitment analytics services.
Multi-Tenant Architecture
The Company�� architecture enables customers to share the same version of its applications while securely partitioning their respective application data. Because customers utilize its information technology (IT) resources and operational infrastructure, this framework reduces the costs of implementation, upgrades, and support.
Object-Oriented Technology Framework
The Company�� applications use objects to represent real-world entities such as employees, benefits, budgets, charts of accounts, and organizations.
In-Memory Data Management
The Company�� use of in-memory processing brings data physically closer to the central processing units and into main memory, eliminating the need to run a disk-seek operation each time a data look-up is performed. This allows for the delivery of embedded business intelligence to facilitate actionable analytics and reporting.
Consumer User Interface (UI)
The Company has built a UI platform that allows it to embrace new UI technologies without needing to rewrite the underlying application logic. It supports all browsers, run natively on Apple�� iOS with applications specifically designed for the iPad and iPhone, and support other mobile platforms such as Android, Windows Mobile and Symbian thro! ugh its HTML5 client.
Configurable Processes
The Company offers a set of tools for configuring, managing, monitoring, and optimizing the business processes that organizations rely on to manage their business. It includes over 270 pre-defined business process definitions to help deployments and provide a starting point for additional configuration.
Web Services-based Integration Platform
By offering an enterprise-class, embedded Web services integration platform and toolset at no additional cost, it relieves customers of many of the burdens associated with legacy systems integration and greatly reduce the risk of implementation failures or delays. In addition to open, standards-based Web services application programming interfaces, it provides a growing portfolio of pre-built, packaged integrations and connectors called Integration Cloud Connect.
Security and Audit
The Company endeavors to adhere to the security standards. It voluntarily obtain third party examinations relating to security and data privacy. It delivers configurable, user-level access control policies as well as a comprehensive, always-on auditing service that captures and documents changes to both data elements and business processes.
The Company competes with Oracle Corporation (Oracle), SAP AG (SAP), Ceridian and NetSuite, Inc.
Advisors' Opinion:- [By Paul Ausick]
Big earnings movers: Chinese internet firm Qihoo 360 Technology Co. Ltd. (NYSE: QIHU) is up 8% at $78.99 on strong earnings and a buoyant outlook. A small biotech firm, Spherix Inc. (NASDAQ: SPEX) jumped 26.7% to more than $14 on earnings. On Tuesday we are scheduled to get earnings from LDK Solar Co. Ltd. (NYSE: LDK) and Tiffany & Co. (NYSE: TIF) before markets open. After Tuesday�� close we��l hear from Workday Inc. (NYSE: WDAY) and TiVo Inc. (NASDAQ: TIVO), among others.
- [By MarketWatch]
Workday (WDAY) �is expected to report a third-quarter loss of 17 cents a share on sales of $117.8 million. Shares of Workday, which offers cloud applications for human resources and finance, have surged around 43% over the past 12 months.
- [By James Oberweis]
In software-as-a-service, take your pick of silliness: Customer relationship manager software firm Salesforce.com (CRM) trades at 104 times estimated 2014 earnings, or human capital management software vendor Workday (WDAY) boasts a P/E of infinity because it earns nothing and isn't expected to be profitable for at least the next couple of years.
- [By John Udovich]
Small cap Paycom Software Inc (NYSE: PAYC) is the latest cloud HR software stock to debut in an IPO, meaning its worth taking a closer look at along with the performance of potential peers like Paylocity Holding Corp (NASDAQ: PCTY), TriNet Group Inc (NYSE: TNET) and Workday Inc (NYSE: WDAY). I should note that I recently wrote about TriNet Group Inc (see: Small Cap TriNet Group Inc (TNET): The Best of the Recent HR Software IPOs? PCTY & WDAY) right after it debuted�with Paylocity Holding Corp also having its IPO a few trading days earlier.
Top Heal Care Companies To Watch For 2014: IMAX Corp (IMAX)
IMAX Corporation, incorporated on January 1, 2002, together with its wholly owned subsidiaries, is an entertainment technology companies, specializing in motion picture technologies and presentations. The Company�� customers who purchase lease or otherwise acquire the IMAX theatre systems are theatre exhibitors, which operate commercial theatres, museums, science centers, and destination entertainment sites. IMAX theatre systems combine the Company�� digital re-mastering movie conversion technology (IMAX DMR), projectors with equipment and automated theatre control systems, sound system components, screens, theatre geometry, and theatre acoustics.
The Company�� principal business is the design, manufacture and delivery of theater systems (IMAX theater systems). The Company�� customers who purchase, lease or otherwise acquire the IMAX theater systems through joint revenue sharing arrangements are theater exhibitors that operate commercial theaters (particularly multiplexes), museums, science centers, or destination entertainment sites. The Company does not own IMAX theaters, but licenses the use of its trademarks along with the sale, lease or contribution of the IMAX theater system.
IMAX Systems, Theater System Maintenance and Joint Revenue Sharing Arrangements
The Company provides IMAX theater systems to customers on a sales or long-term lease basis with an initial 10-year term. These agreements consist of initial fees and ongoing fees (which can include a fixed minimum amount per annum and contingent fees in excess of the minimum payments) and maintenance and extended warranty fees. The initial fees vary depending on the system configuration and location of the theater and generally are paid to the Company in installments between the time of system signing and the time of system installation. Ongoing fees are paid over the term of the contract, commencing after the theater system has been installed and are generally equal to the greater of a fixed minimu! m amount per annum or a percentage of boxoffice receipts. The Company also provides IMAX theater systems to customers under joint revenue sharing arrangements, pursuant to which the Company provides the IMAX theater system in return for a portion of the customer�� IMAX box-office receipts, and in some cases concession revenues and/or a small upfront or initial payment. As at December 31, 2012, the Company had 316 theaters in operation under joint revenue sharing arrangements.
Production and Digital Re-Mastering (IMAX DMR)
The Company�� technology digitally re-masters Hollywood films into IMAX digital cinema package format or 15/70-format film. IMAX DMR digitally enhances the image resolution of motion picture films for projection on IMAX screens while maintaining or enhancing the visual clarity and sound quality to levels for which The IMAX Experience is known. This technology enabled the IMAX theater network to release Hollywood films simultaneously with domestic release. In a typical IMAX DMR film arrangement, the Company will receive a percentage of net box-office receipts of any commercial films released in the IMAX network, which is generally 10-15%, from a film studio for the conversion of the film to the IMAX DMR format and access to its distribution platform. During the year ended December 31, 2012, 35 films converted through the IMAX DMR process were released to theaters within the IMAX network. As of December 31, 2012, the Company released 23 IMAX DMR titles to theaters within the IMAX network. During 2012, five local language IMAX DMR films were released, including one French film, Houba! On the Trail of the Marsupilami: The IMAX Experience and four Chinese IMAX DMR titles: Tai Chi 0: An IMAX 3D Experience, Tai Chi Hero: An IMAX 3D Experience, Back to 1942: The IMAX Experience and CZ12: The IMAX Experience.
Film Distribution and Post-Production
The Company is also a distributor of large-format films, primarily catering to its institution! al theate! r partners. The Company generally distributes films, which it produces or for which it has acquired distribution rights from independent producers. The Company generally receives a percentage of the theater box-office receipts as a distribution fee. Films produced by the Company are typically financed through third parties, whereby the Company will generally receive a film production fee in exchange for producing the film and a distribution fee for distributing the film. The Company utilizes third-party funding for the majority of original films it produces and distributes. In 2012, the Company, along with Warner Bros. Pictures (WB) and MacGillivray Freeman Films (MFF) released an original title, To the Artic 3D: An IMAX 3D Experience.
The Company derives a small portion of its revenues from other sources. As of December 31, 2012, the Company had four owned and operated theaters. In addition, the Company has a commercial arrangement with one theater resulting in the sharing of profits and losses and provides management services to two theaters. The Company also rents its two dimensional (2D) and three dimensional (3D) large-format film and digital cameras to third party production companies. The Company maintains cameras and other film equipment and also offers production advice and technical assistance to both documentary and Hollywood filmmakers. Additionally, the Company generates revenues from the sale of after-market parts and 3D glasses. As of December 31, 2012, approximately 54.2% of IMAX systems in operation were located in the United States and Canada. As at December 31, 2012, approximately 45.8% of IMAX systems in operation were located within international markets (other than the United States and Canada).
Advisors' Opinion:- [By Tim Beyers]
Iron Man 3 is a huge hit everywhere, especially in China, where IMAX (NYSE: IMAX ) booked $1.8 million in gross receipts -- a new record -- as Walt Disney (NYSE: DIS ) set a high watermark of its own.
No comments:
Post a Comment